Telaprevir is an NS3/4A viral protease inhibitor used in combination with other antivirals for the curative treatment of chronic Hepatitis C Virus infections. Telaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).
- Mechanism
- Curator reviewed
Telaprevir is a NS3/4a protease inhibitor used to inhibit viral HCV replication. NS3/4a protease is an integral part of viral replication and mediates the cleavage the virally encoded polyprotein to mature proteins (NS4A, NS4B, NS5A and NS5B). Telaprevir inhibits NS3/4A with an IC50 of 10nM.
- Primary indication
- Telaprevir, when used in combination with DB00811, DB00008, and DB00022 is indicated for use in the treatment of chronic HCV genotype 1 infection in adults.Curator reviewed · 2 structured indications
- Formula / weight
- C36H53N7O6 · 679.8493 g/mol (avg)
- First approval
- Canada, 2011 · United States, 2011
- Code names
- AIDS-213006 · LY-570310 · MP-424 · VRT-111950 · VX-950
Resolves to
BBAWEDCPNXPBQM-GDEBMMAJSA-NSMILES[H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1What you can answer from here — as of January 29, 2025
Which drugs share a target with Telaprevir, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account